Biological medicines for asthma

RX_ASTMA_BIOL

No definition available.

Endpoint definition

FinnGen phenotype data

392423 individuals

diagram downward connector

Apply sex-specific rule None

392423

diagram downward connector

Check conditions None

392423

diagram downward connector
diagram bullet

Check pre-conditions, main-only, mode, registry filters

Medicine purchases: ATC R03DX05|R03DX08|R03DX09|R03DX10|D11AH05

1 out of 7 registries used, show all original rules.

180

diagram downward connector
diagram bullet

Check minimum number of events

Min. number of events 3

180

diagram downward connector

Include endpoints None

180

diagram downward connector
diagram bullet diagram downward connector

Remove individuals based on genotype QC

175

diagram downward connector
RX_ASTMA_BIOL

Control definitions

Controls for this endpoint are individuals that are not cases.

Extra metadata

First used in FinnGen datafreeze DF5

Summary Statistics

Key figures

All Female Male
Number of individuals 175 105 70
Unadjusted prevalence (%) 0.05 0.05 0.04
Mean age at first event (years) 51.63 51.18 52.30

Mortality

Follow-up Absolute risk HR [95% CI] p N
1998–2019 - - - -
15 years - - - -
5 years - - - -
1 year - - - -

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Correlations

Index endpoint: RX_ASTMA_BIOL – Biological medicines for asthma
GWS hits:

Survival analyses between endpoints

Not a core endpoint, no data to show.

Drugs most likely to be purchased after Biological medicines for asthma

Endpoint not on priority list, no data to show.